蚕沙有机肥的养分特性及其肥效

将废弃蚕沙进行无害化处理和适度发酵开发出蚕沙有机肥,分析了其养分特点,并采用盆栽试验研究了蚕沙有机肥的肥效.结果表明:发酵蚕沙有机肥的全氮、全磷、全钾含量与堆肥前相比显著提高,分别比堆肥前提高了58.0%、84.4%和29.7%;添加微生物菌剂可有效缩短发酵时间,并能减少堆肥过程的碳、氮损失.施用发酵后蚕沙的小白菜和番茄种子的发芽指数均大于80%,对作物发芽没有抑制作用.施用发酵蚕沙有机肥不仅可提高小白菜产量、营养养分、Vc含量,减少硝酸盐积累量,还可提高土壤pH值,增加土壤速效养分和有机质含量,增强土壤酶活性,其效果优于发酵羊粪有机肥处理.     

黑麦草根系分泌物剂量对污染土壤芘降解和土壤微生物的影响

模拟根际根系分泌物梯度递减效应,研究了黑麦草根系分泌物剂量对污染土壤中芘降解特征和土壤微生物生态特征的影响.结果表明:污染土壤中芘残留量随根系分泌物添加剂量的增加呈现先下降后上升的非线性变化,达到最低芘残留量的添加剂量是总有机碳(TOC) 32.75 mg·kg-1,说明此浓度下根系分泌物显著促进了芘的降解;土壤微生物生物量碳和微生物熵的变化趋势与污染土壤中芘残留量变化趋势相反,表明土壤微生物与污染土壤 中芘残留量存在密切关系.芘污染土壤中微生物群落以细菌占主导地位,且细菌变化趋势与芘降解变化一致,表明芘以细菌降解为主,根系分泌物主要通过影响细菌数量,进而影响芘的降解.能催化有机物质脱氢反应的土壤微生物胞内酶——脱氢酶活性的变化与土壤微生物变化趋势一致,进一步证明微生物及其生物化学特性变化是污染土壤中芘残留量随根系分泌物添加剂量变化的生态机制.     

Probiotic (symbiotic) bacterial languages

Symbiotic gut microorganisms release of various soluble low molecular weight (LMW)molecules of different chemical nature (surface and exogenous proteins, nucleases, serpins, sirtuines, other enzymes, lectins, peptides, amines, bacteriocines, fatty and amino acids, lactones, furanons, miRNA, NO, etc). These LMW molecules are able to sense environment, interact with corresponding cell surface, membrane, cytoplasm and nucleic acid receptors, to reply quickly and coordinately by induction of special sets of genes, to support stability of host genome and microbiome, to modulate epigenomic regulation of gene phenotypic expression, to ensure the information exchange in numerous bacterial and bacteria-host systems playing an important role in the control for many genetic and physiological functions, biochemical and behaviour reactions, in supporting host health in general. Various symbiotic (probiotic) strains produce different spectrum of such LMW molecules. There is chemical and functional similarity between LMW molecules synthesized by host eukaryotic cells, indigenous and probiotic microorganisms and some micronutrients. It means many LMW compounds of different origin may be the universal regulators contributing to the transmission of information, quorum sensing effects, metagenome stability and epigenomic control for cell growth and development as well as phenotypic expression of different genes. Knowledge accumulated concerning molecular languages of symbiotic microorganisms allows us to better understand the mode of action of known probiotics and to design in principle novel probiotics (metabiotics) with increased health effectiveness. Now we are only at the beginning of a new era of molecular personal biotherapy and nutrition. Soon we can successfully manipulate both the host and its microbiota through interfering in their cross talk, stability and epigenomic regulation of expression of genes using various types of eukaryotic, prokaryotic and nutrition origin LMW molecules are capable to modulate genetic, metabolic and physiological activities.     

Role of the probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes in influencing faecal bacteria and biochemical parameters in human subjects

Aims: To evaluate the positive influence of the probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes into the human gut with special reference to faecal bacterial balance, short‐chain fatty acid concentrations and enzyme activities in a randomized, double‐blind human trial in comparison with probiotic‐free artichokes (control). Methods: Twenty subjects were randomized into two groups, which consumed daily 180 g of the artichoke product (probiotic or control) during two 15‐day study periods (periods 1 and 2) separated by a 15‐day washout in a crossover manner. Faecal samples were subjected to microbiological and biochemical analyses, and a strain‐specific PCR was performed to monitor the probiotic strain. Results: The probiotic strain, transported by the vegetable matrix, transiently colonized the gut of 17/20 subjects (median 6·87 log CFU g^?1 faeces), antagonized Escherichia coli and Clostridium spp. and increased the genetic diversity of lactic population based on REP‐PCR profiles, mainly after period 1. Conclusions: The probiotic L. paracasei LMGP22043 successfully colonized the human gut and positively influenced faecal bacteria and biochemical parameters. Significance and Impact of the Study: The association of the probiotic L. paracasei with a food carrier rich in fibre can represent a new strategy for favouring a daily supply of probiotics and attracting more consumers to vegetable food fortified with probiotic strains.     

Quantifying agonist activity at G protein-coupled receptors

When an agonist activates a population of G protein-coupled receptors (GPCRs), it elicits a signaling pathway that culminates in the response of the cell or tissue. This process can be analyzed at the level of a single receptor, a population of receptors, or a downstream response. Here we describe how to analyze the downstream response to obtain an estimate of the agonist affinity constant for the active state of single receptors. Receptors behave as quantal switches that alternate between active and inactive states (Figure 1). The active state interacts with specific G proteins or other signaling partners. In the absence of ligands, the inactive state predominates. The binding of agonist increases the probability that the receptor will switch into the active state because its affinity constant for the active state (K(b)) is much greater than that for the inactive state (K(a)). The summation of the random outputs of all of the receptors in the population yields a constant level of receptor activation in time. The reciprocal of the concentration of agonist eliciting half-maximal receptor activation is equivalent to the observed affinity constant (K(obs)), and the fraction of agonist-receptor complexes in the active state is defined as efficacy (ε) (Figure 2). Methods for analyzing the downstream responses of GPCRs have been developed that enable the estimation of the K(obs) and relative efficacy of an agonist. In this report, we show how to modify this analysis to estimate the agonist K(b) value relative to that of another agonist. For assays that exhibit constitutive activity, we show how to estimate K(b) in absolute units of M(-1). Our method of analyzing agonist concentration-response curves consists of global nonlinear regression using the operational model. We describe a procedure using the software application, Prism (GraphPad Software, Inc., San Diego, CA). The analysis yields an estimate of the product of K(obs) and a parameter proportional to efficacy (τ). The estimate of τK(obs) of one agonist, divided by that of another, is a relative measure of K(b) (RA(i)). For any receptor exhibiting constitutive activity, it is possible to estimate a parameter proportional to the efficacy of the free receptor complex (τ(sys)). In this case, the K(b) value of an agonist is equivalent to τK(obs)/τ(sys). Our method is useful for determining the selectivity of an agonist for receptor subtypes and for quantifying agonist-receptor signaling through different G proteins.     

The 29.9 kDa subunit of mitochondrial complex I is involved in the enzyme active/de-active transitions

Mitochondrial respiratory chain complex I undergoes transitions from active to de-activated forms. We have investigated the phenomenon in sub-mitochondrial particles from Neurospora crassa wild-type and a null-mutant lacking the 29.9 kDa nuclear-coded subunit of complex I. Based on enzymatic activities, genetic crosses and analysis of mitochondrial proteins in sucrose gradients, we found that about one-fifth of complex I with catalytic properties similar to the wild-type enzyme is assembled in the mutant. Mutant complex I still displays active/de-active transitions, indicating that other proteins are involved in the phenomenon. However, the kinetic characteristics of complex I active/de-active transitions in nuo29.9 differ from wild-type. The spontaneous de-activation of the mutant enzyme is much slower, implicating the 29.9 kDa polypeptide in this event. We suggest that the fungal 29.9 kDa protein and its homologues in other organisms may modulate the active/de-active transitions of complex I.     

Crystal structure of truncated Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase in complex with beta-1,3-1,4-cellotriose

Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase (Fsbeta-glucanase) catalyzes the specific hydrolysis of beta-1,4 glycosidic bonds adjacent to beta-1,3 linkages in beta-D-glucans or lichenan. This is the first report to elucidate the crystal structure of a truncated Fsbeta-glucanase (TFsbeta-glucanase) in complex with beta-1,3-1,4-cellotriose, a major product of the enzyme reaction. The crystal structures, at a resolution of 2.3 angstroms, reveal that the overall fold of TFsbeta-glucanase remains virtually unchanged upon sugar binding. The enzyme accommodates five glucose residues, forming a concave active cleft. The beta-1,3-1,4-cellotriose with subsites -3 to -1 bound to the active cleft of TFsbeta-glucanase with its reducing end subsite -1 close to the key catalytic residues Glu56 and Glu60. All three subsites of the beta-1,3-1,4-cellotriose adopted a relaxed C(1)4 conformation, with a beta-1,3 glycosidic linkage between subsites -2 and -1, and a beta-1,4 glycosidic linkage between subsites -3 and -2. On the basis of the enzyme-product complex structure observed in this study, a catalytic mechanism and substrate binding conformation of the active site of TFsbeta-glucanase is proposed.     

HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells

Among the different factors which can contribute to CNS alterations associated with HIV infection, Tat protein is considered to play a critical role. Evidence indicates that Tat can contribute to brain vascular pathology through induction of endothelial cell activation. In the present study, we hypothesized that Tat can affect expression of P-glycoprotein (P-gp) in brain microvascular endothelial cells (BMEC). P-gp is an ATP-dependent cellular efflux transporter which is involved in the removal of specific non-polar molecules, including drugs used for highly active antiretroviral therapy (HAART). Treatment of BMEC with Tat(1-72) resulted in P-gp overexpression both at mRNA and protein levels. These alterations were confirmed in vivo in brain vessels of mice injected with Tat(1-72) into the hippocampus. Furthermore, pre-treatment of BMEC with SN50, a specific NF-kappaB inhibitor, protected against Tat(1-72)-stimulated expression of mdr1a gene, i.e. the gene which encodes for P-gp in rodents. Tat(1-72)-mediated changes in P-gp expression were correlated with increased rhodamine 123 efflux, indicating the up-regulation of transporter functions of P-gp. These results suggest that Tat-induced overexpression of P-gp in brain microvessels may have significant implications for the development of resistance to HAART and may be a contributing factor for low efficacy of HAART in the CNS.